perfosfamide has been researched along with Lung Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckett, MA; Gupta, VK; Koons, A; Kufe, DW; Lee, JY; Manan, A; Mauceri, HJ; Montag, AG; Park, JO; Schumm, LP; Seetharam, S; Weichselbaum, RR | 1 |
| Mohuczy, D; Moreb, JS; Muhoczy, D; Ostmark, B; Zucali, JR | 1 |
| Benson, NA; Moreb, JS; Ostmark, B; Zucali, JR | 1 |
| Kaddurah-Daouk, R; Kufe, DW; Liu, J; Menon, K; Northey, D; Teicher, BA | 1 |
| Hecomovich, J; Maccow, C; Moreb, JS; Schweder, M | 1 |
| Luk, GD; Tsai, DC | 1 |
6 other study(ies) available for perfosfamide and Lung Neoplasms
| Article | Year |
|---|---|
Angiostatin potentiates cyclophosphamide treatment of metastatic disease.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cells, Cultured; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Endothelium, Vascular; Humans; Linear Models; Lung Neoplasms; Mice; Mice, Inbred C57BL; Morphogenesis; Neoplasm Metastasis; Neovascularization, Physiologic; Peptide Fragments; Plasminogen; Protein Synthesis Inhibitors; Single-Blind Method; Tumor Cells, Cultured | 2002 |
RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide.
Topics: Actins; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cyclophosphamide; DNA Primers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Retinal Dehydrogenase; Retroviridae; RNA Interference; Substrate Specificity; Tretinoin | 2007 |
Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Lung Neoplasms; Propidium; Retinal Dehydrogenase; RNA, Small Interfering; Staining and Labeling | 2007 |
Cyclocreatine in cancer chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Carmustine; Cell Division; Cell Survival; Cisplatin; Creatinine; Cyclophosphamide; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Lung Neoplasms; Mammary Neoplasms, Experimental; Melphalan; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 1995 |
Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro.
Topics: Aldehyde Dehydrogenase; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; DNA, Neoplasm; Genetic Vectors; Humans; Leukemia, Experimental; Lung Neoplasms; RNA, Antisense; RNA, Messenger; Transfection; Tumor Cells, Cultured | 2000 |
The growth-inhibitory effect of 4-hydroperoxycyclophosphamide against human non-small cell lung carcinoma is enhanced by low-dose difluoromethylornithine.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Eflornithine; Humans; Lung Neoplasms; Tumor Cells, Cultured | 1988 |